中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
25期
34-35
,共2页
新辅助化疗%结肠癌%临床效果
新輔助化療%結腸癌%臨床效果
신보조화료%결장암%림상효과
The new adjuvant chemotherapy%Colon cancer%Clinical effect
目的:探究新辅助化疗对结肠癌患者手术以及预后的影响。方法结肠癌患者50例,随机分为试验组和对照组,每组25例,试验组采用新辅助化疗法,对照组采用常规疗法,对比两组治疗效果及预后。结果治疗前后对照组CD44v6、p27蛋白等指标对比差异无统计学意义,试验组差异有统计学意义(P<0.05),其中CD44v6蛋白指标发生显著下降, p27蛋白指标明显上升。两组预后对比,试验组治疗及恢复情况优于对照组,对照组则多出现呕吐、恶心、食欲不振、抵抗力差等情况。结论新辅助化疗对于结肠癌患者的治疗和预后有显著效果,值得在临床中推广使用。
目的:探究新輔助化療對結腸癌患者手術以及預後的影響。方法結腸癌患者50例,隨機分為試驗組和對照組,每組25例,試驗組採用新輔助化療法,對照組採用常規療法,對比兩組治療效果及預後。結果治療前後對照組CD44v6、p27蛋白等指標對比差異無統計學意義,試驗組差異有統計學意義(P<0.05),其中CD44v6蛋白指標髮生顯著下降, p27蛋白指標明顯上升。兩組預後對比,試驗組治療及恢複情況優于對照組,對照組則多齣現嘔吐、噁心、食欲不振、牴抗力差等情況。結論新輔助化療對于結腸癌患者的治療和預後有顯著效果,值得在臨床中推廣使用。
목적:탐구신보조화료대결장암환자수술이급예후적영향。방법결장암환자50례,수궤분위시험조화대조조,매조25례,시험조채용신보조화요법,대조조채용상규요법,대비량조치료효과급예후。결과치료전후대조조CD44v6、p27단백등지표대비차이무통계학의의,시험조차이유통계학의의(P<0.05),기중CD44v6단백지표발생현저하강, p27단백지표명현상승。량조예후대비,시험조치료급회복정황우우대조조,대조조칙다출현구토、악심、식욕불진、저항력차등정황。결론신보조화료대우결장암환자적치료화예후유현저효과,치득재림상중추엄사용。
Objective To explore the new adjuvant chemotherapy in patients with colon cancer surgery and prognosis. Methods 50 patients with colon cancer, were randomly divided into trial group and control group, 25 cases in each group, experimental group using the method of neoadjuvant chemotherapy, the control group with conventional therapy. Compared two groups of therapeutic effect and prognosis. Results Before and after treatment, when test CD44v6 and p27 protein indexes of the control group, there was no statistically significant difference. But there was statistically significant difference before and after treatment of the trial group (P<0.05), of which the CD44v6 protein index dropped significantly while p27 protein index increased significantly. Treatment and prognosis of two groups, test group recovery is better than that of control group. Control group are vomiting, nausea, loss of ap-petite, poor resistance. Conclusion Neoadjuvant chemotherapy for the treatment and prognosis of patients with colon cancer has a significant effect. It is worth popularizing in clinical use.